{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:44:05Z","timestamp":1793295845500,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["6542-18"],"award-info":[{"award-number":["6542-18"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["2319-19"],"award-info":[{"award-number":["2319-19"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1038\/s41375-020-0794-0","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T21:03:25Z","timestamp":1584392605000},"page":"156-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells"],"prefix":"10.1038","volume":"35","author":[{"given":"Scott","family":"Best","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vi","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Bruss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kittai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga V.","family":"Danilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D.","family":"Pennock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7026-2012","authenticated-orcid":false,"given":"Evan F.","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0970","authenticated-orcid":false,"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"key":"794_CR1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11899-019-00511-1","volume":"14","author":"AS Kittai","year":"2019","unstructured":"Kittai AS, Lunning M, Danilov AV. Relevance of prognostic factors in the era of targeted therapies in CLL. Curr Hematol Malig Rep. 2019;14:302\u20139.","journal-title":"Curr Hematol Malig Rep"},{"key":"794_CR2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bjh.13042","volume":"167","author":"P Shindiapina","year":"2014","unstructured":"Shindiapina P, Brown JR, Danilov AV. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. Br J Haematol. 2014;167:149\u201361.","journal-title":"Br J Haematol"},{"key":"794_CR3","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","volume":"127","author":"M Long","year":"2017","unstructured":"Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Investig. 2017;127:3052\u201364.","journal-title":"J Clin Investig"},{"key":"794_CR4","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539\u201349.","journal-title":"Blood"},{"key":"794_CR5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","volume":"128","author":"BL Lampson","year":"2016","unstructured":"Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195\u2013203.","journal-title":"Blood"},{"key":"794_CR6","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","volume":"132","author":"A Bercusson","year":"2018","unstructured":"Bercusson A, Colley T, Shah A, Warris A, Armstrong-James D. Ibrutinib blocks Btk-dependent NF-kB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood. 2018;132:1985\u20138.","journal-title":"Blood"},{"key":"794_CR7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/cr.2016.31","volume":"26","author":"X Huang","year":"2016","unstructured":"Huang X, Dixit VM. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 2016;26:484\u201398.","journal-title":"Cell Res"},{"key":"794_CR8","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","volume":"116","author":"MA Milhollen","year":"2010","unstructured":"Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood. 2010;116:1515\u201323.","journal-title":"Blood"},{"key":"794_CR9","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.161","volume":"6","author":"C Paiva","year":"2015","unstructured":"Paiva C, Godbersen JC, Berger A, Brown JR, Danilov AV. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents. Cell Death Dis. 2015;6:e1807.","journal-title":"Cell Death Dis"},{"key":"794_CR10","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-13-0987","volume":"20","author":"JC Godbersen","year":"2014","unstructured":"Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, et al. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-kappaB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res. 2014;20:1576\u201389.","journal-title":"Clin Cancer Res"},{"key":"794_CR11","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732\u20136.","journal-title":"Nature"},{"key":"794_CR12","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-13-0987","volume":"20","author":"JC Godbersen","year":"2014","unstructured":"Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, et al. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-\u03baB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res. 2014;20:1576\u201389.","journal-title":"Clin Cancer Res"},{"key":"794_CR13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/imr.12033","volume":"252","author":"H Oh","year":"2013","unstructured":"Oh H, Ghosh S. NF-kappaB: roles and regulation in different CD4(+) T-cell subsets. Immunol Rev. 2013;252:41\u201351.","journal-title":"Immunol Rev"},{"key":"794_CR14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.it.2013.02.002","volume":"34","author":"S Paul","year":"2013","unstructured":"Paul S, Schaefer BC. A new look at T cell receptor signaling to nuclear factor-kappaB. Trends Immunol. 2013;34:269\u201381.","journal-title":"Trends Immunol"},{"key":"794_CR15","doi-asserted-by":"crossref","first-page":"45263","DOI":"10.18632\/oncotarget.9481","volume":"7","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Shi CC, Zhang HP, Li GQ, Li SS. MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma. Oncotarget. 2016;7:45263\u201374.","journal-title":"Oncotarget"},{"key":"794_CR16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-1-4614-0106-3_12","volume":"946","author":"Q Ruan","year":"2012","unstructured":"Ruan Q, Chen YH. Nuclear factor-kappaB in immunity and inflammation: the Treg and Th17 connection. Adv Exp Med Biol. 2012;946:207\u201321.","journal-title":"Adv Exp Med Biol"},{"key":"794_CR17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.immuni.2009.09.022","volume":"31","author":"M Long","year":"2009","unstructured":"Long M, Park SG, Strickland I, Hayden MS, Ghosh S. Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity. 2009;31:921\u201331.","journal-title":"Immunity"},{"key":"794_CR18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/intimm\/dxn002","volume":"20","author":"L Passerini","year":"2008","unstructured":"Passerini L, Allan SE, Battaglia M, Di Nunzio S, Alstad AN, Levings MK, et al. STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells. Int Immunol. 2008;20:421\u201331.","journal-title":"Int Immunol"},{"key":"794_CR19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","volume":"24","author":"M Veldhoen","year":"2006","unstructured":"Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179\u201389.","journal-title":"Immunity"},{"key":"794_CR20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235\u20138.","journal-title":"Nature"},{"key":"794_CR21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.cell.2011.07.033","volume":"146","author":"EV Dang","year":"2011","unstructured":"Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17\/T(reg) balance by hypoxia-inducible factor 1. Cell. 2011;146:772\u201384.","journal-title":"Cell"},{"key":"794_CR22","doi-asserted-by":"crossref","first-page":"cm8","DOI":"10.1126\/stke.4072007cm8","volume":"2007","author":"GL Semenza","year":"2007","unstructured":"Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE. 2007;2007:cm8.","journal-title":"Sci STKE"},{"key":"794_CR23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.169.1.59","volume":"169","author":"FP Heinzel","year":"1989","unstructured":"Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med. 1989;169:59\u201372.","journal-title":"J Exp Med"},{"key":"794_CR24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1084\/jem.181.2.713","volume":"181","author":"CS Hsieh","year":"1995","unstructured":"Hsieh CS, Macatonia SE, O\u2019Garra A, Murphy KM. T cell genetic background determines default T helper phenotype development in vitro. J Exp Med. 1995;181:713\u201321.","journal-title":"J Exp Med"},{"key":"794_CR25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1006\/cimm.1998.1406","volume":"191","author":"TL Wagner","year":"1999","unstructured":"Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Smith RM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol. 1999;191:10\u201319.","journal-title":"Cell Immunol"},{"key":"794_CR26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1006\/cimm.2000.1689","volume":"204","author":"JP Vasilakos","year":"2000","unstructured":"Vasilakos JP, Smith RM, Gibson SJ, Lindh JM, Pederson LK, Reiter MJ, et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol. 2000;204:64\u201374.","journal-title":"Cell Immunol"},{"key":"794_CR27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-15-1237","volume":"22","author":"JJ Shah","year":"2016","unstructured":"Shah JJ, Jakubowiak AJ, O\u2019Connor OA, Orlowski RZ, Harvey RD, Smith MR, et al. Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed\/refractory multiple myeloma or lymphoma. Clin Cancer Res. 2016;22:34\u201343.","journal-title":"Clin Cancer Res"},{"key":"794_CR28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood.V100.1.167","volume":"100","author":"AM Krackhardt","year":"2002","unstructured":"Krackhardt AM, Harig S, Witzens M, Broderick R, Barrett P, Gribben JG. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood. 2002;100:167\u201373.","journal-title":"Blood"},{"key":"794_CR29","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/bloodadvances.2017006809","volume":"1","author":"K Maharaj","year":"2017","unstructured":"Maharaj K, Sahakian E, Pinilla-Ibarz J. Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia. Blood Adv. 2017;1:1867\u201375.","journal-title":"Blood Adv"},{"key":"794_CR30","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.4049\/jimmunol.1601190","volume":"198","author":"Q Yin","year":"2017","unstructured":"Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O\u2019Brien S, et al. Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia. J Immunol. 2017;198:1740\u20137.","journal-title":"J Immunol"},{"key":"794_CR31","first-page":"2427","volume":"118","author":"AG Ramsay","year":"2008","unstructured":"Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Investig. 2008;118:2427\u201337.","journal-title":"J Clin Investig"},{"key":"794_CR32","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-08-448332","volume":"121","author":"AG Ramsay","year":"2013","unstructured":"Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood. 2013;121:2704\u201314.","journal-title":"Blood"},{"key":"794_CR33","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3109\/10428194.2014.990901","volume":"56","author":"JC Godbersen","year":"2015","unstructured":"Godbersen JC, Paiva C, Danilova OV, Berger A, Brown JR, Danilov AV. Targeting neddylation effectively antagonizes nuclear factor-kappaB in chronic lymphocytic leukemia B-cells. Leuk Lymphoma. 2015;56:1566\u20139.","journal-title":"Leuk Lymphoma"},{"key":"794_CR34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","volume":"36","author":"SH Ross","year":"2018","unstructured":"Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes. Annu Rev Immunol. 2018;36:411\u201333.","journal-title":"Annu Rev Immunol"},{"key":"794_CR35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/0008-5472.CAN-12-1729","volume":"73","author":"JL Blank","year":"2013","unstructured":"Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, et al. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Cancer Res. 2013;73:225\u201334.","journal-title":"Cancer Res"},{"key":"794_CR36","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1073\/pnas.1213819110","volume":"110","author":"HS Jin","year":"2013","unstructured":"Jin HS, Liao L, Park Y, Liu YC. Neddylation pathway regulates T-cell function by targeting an adaptor protein Shc and a protein kinase Erk signaling. Proc Natl Acad Sci USA. 2013;110:624\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"794_CR37","doi-asserted-by":"crossref","first-page":"e75200","DOI":"10.1371\/journal.pone.0075200","volume":"8","author":"SF Friend","year":"2013","unstructured":"Friend SF, Peterson LK, Treacy E, Stefanski AL, Sosinowski T, Pennock ND, et al. The discovery of a reciprocal relationship between tyrosine-kinase signaling and cullin neddylation. PLoS ONE. 2013;8:e75200.","journal-title":"PLoS ONE"},{"key":"794_CR38","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.celrep.2018.10.002","volume":"25","author":"MY Fan","year":"2018","unstructured":"Fan MY, Low JS, Tanimine N, Finn KK, Priyadharshini B, Germana SK, et al. Differential roles of IL-2 signaling in developing versus mature tregs. Cell Rep. 2018;25:1204\u2013.e1204.","journal-title":"Cell Rep"},{"key":"794_CR39","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1007\/s00018-017-2569-y","volume":"74","author":"A Kitz","year":"2017","unstructured":"Kitz A, Dominguez-Villar M. Molecular mechanisms underlying Th1-like Treg generation and function. Cell Mol Life Sci. 2017;74:4059\u201375.","journal-title":"Cell Mol Life Sci"},{"key":"794_CR40","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/CBI20100528","volume":"35","author":"E Shen","year":"2011","unstructured":"Shen E, Zhao K, Wu C, Yang B. The suppressive effect of CD25+Treg cells on Th1 differentiation requires cell-cell contact partially via TGF-beta production. Cell Biol Int. 2011;35:705\u201312.","journal-title":"Cell Biol Int"},{"key":"794_CR41","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/ni.1731","volume":"10","author":"MA Koch","year":"2009","unstructured":"Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol. 2009;10:595\u2013602.","journal-title":"Nat Immunol"},{"key":"794_CR42","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1073\/pnas.0400339101","volume":"101","author":"J Cote-Sierra","year":"2004","unstructured":"Cote-Sierra J, Foucras G, Guo L, Chiodetti L, Young HA, Hu-Li J, et al. Interleukin 2 plays a central role in Th2 differentiation. Proc Natl Acad Sci USA. 2004;101:3880\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"794_CR43","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.2012.077537","volume":"98","author":"D Brusa","year":"2013","unstructured":"Brusa D, Serra S, Coscia M, Rossi D, D\u2019Arena G, Laurenti L, et al. The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013;98:953\u201363.","journal-title":"Haematologica"},{"key":"794_CR44","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2012.165","volume":"27","author":"DJ DiLillo","year":"2013","unstructured":"DiLillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y, et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia. 2013;27:170\u201382.","journal-title":"Leukemia"},{"key":"794_CR45","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/cncr.22094","volume":"107","author":"S Francis","year":"2006","unstructured":"Francis S, Karanth M, Pratt G, Starczynski J, Hooper L, Fegan C, et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer. 2006;107:1023\u201333.","journal-title":"Cancer"},{"key":"794_CR46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","volume":"27","author":"JC Riches","year":"2013","unstructured":"Riches JC, Gribben JG. Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. Hematol Oncol Clin N Am. 2013;27:207\u201335.","journal-title":"Hematol Oncol Clin N Am"},{"key":"794_CR47","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","volume":"126","author":"F Forconi","year":"2015","unstructured":"Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573\u201381.","journal-title":"Blood"},{"key":"794_CR48","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","volume":"121","author":"JC Riches","year":"2013","unstructured":"Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121:1612\u201321.","journal-title":"Blood"},{"key":"794_CR49","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","volume":"115","author":"G Gorgun","year":"2005","unstructured":"Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Investig. 2005;115:1797\u2013805.","journal-title":"J Clin Investig"},{"key":"794_CR50","doi-asserted-by":"crossref","first-page":"E730","DOI":"10.3390\/ijms19030730","volume":"19","author":"GR Lee","year":"2018","unstructured":"Lee GR. The balance of Th17 versus Treg cells in autoimmunity. Int J Mol Sci. 2018;19:E730.","journal-title":"Int J Mol Sci."},{"key":"794_CR51","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2017-09-805895","volume":"131","author":"RT Swords","year":"2018","unstructured":"Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, et al. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 2018;131:1415\u201324.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0794-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0794-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0794-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:39:55Z","timestamp":1684618795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0794-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["794"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0794-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,16]]},"assertion":[{"value":"9 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AVD has received research funding from Astra Zeneca, Gilead Sciences, Genentech, Aptose Biosciences, MEI Pharma, Takeda Oncology, Bayer Oncology, Verastem Oncology, and Bristol-Meyers-Squibb; honoraria from Astra Zeneca, Celgene, Curis, Genentech, Gilead Sciences, Janssen Oncology, Pharmacyclics, Seattle Genetics, TG Therapeutics, and Verastem Oncology. EFL has received research funding from Celgene, Amgen, Janssen Pharmaceuticals, Monojul, and Kyn Therapeutics. AB is employed by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}